Search

Carol M. Koslow

Examiner (ID: 12920, Phone: (571)272-1371 , Office: P/1734 )

Most Active Art Unit
1734
Art Unit(s)
1734, 1754, 1793, 1755, 1108
Total Applications
5011
Issued Applications
4022
Pending Applications
258
Abandoned Applications
784

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 15239549 [patent_doc_number] => 20190374560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/450836 [patent_app_country] => US [patent_app_date] => 2019-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16450836 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/450836
SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE Jun 23, 2019 Abandoned
Array ( [id] => 16791717 [patent_doc_number] => 20210121534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => SUSTAINED-RELEASE DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A CNP COMPOUND, AN NPR-B COMPOUND, A TIE-2 AGONIST, OR NEUROTROPHIC AGENT FOR USE FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION [patent_app_type] => utility [patent_app_number] => 17/254617 [patent_app_country] => US [patent_app_date] => 2019-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21009 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17254617 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/254617
SUSTAINED-RELEASE DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A CNP COMPOUND, AN NPR-B COMPOUND, A TIE-2 AGONIST, OR NEUROTROPHIC AGENT FOR USE FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION Jun 17, 2019 Pending
Array ( [id] => 15264447 [patent_doc_number] => 20190380957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => Protein Hydrogels For Treatment Of Neovascular Disease [patent_app_type] => utility [patent_app_number] => 16/442044 [patent_app_country] => US [patent_app_date] => 2019-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5897 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16442044 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/442044
Protein Hydrogels For Treatment Of Neovascular Disease Jun 13, 2019 Abandoned
Array ( [id] => 15649631 [patent_doc_number] => 20200087345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => MODULATION OF P53 FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/422850 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16422850 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/422850
Modulation of P53 for the treatment of cancer May 23, 2019 Issued
Array ( [id] => 14864869 [patent_doc_number] => 20190282676 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => HEMOSTATIC COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/421094 [patent_app_country] => US [patent_app_date] => 2019-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10567 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16421094 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/421094
HEMOSTATIC COMPOSITIONS May 22, 2019 Abandoned
Array ( [id] => 15035653 [patent_doc_number] => 20190328831 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 [patent_app_type] => utility [patent_app_number] => 16/411944 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16411944 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/411944
METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 May 13, 2019 Abandoned
Array ( [id] => 16868433 [patent_doc_number] => 20210161900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF SENESCENT TUMOR CELLS [patent_app_type] => utility [patent_app_number] => 17/047258 [patent_app_country] => US [patent_app_date] => 2019-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10686 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17047258 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/047258
COMPOSITIONS AND METHODS FOR THE TREATMENT OF SENESCENT TUMOR CELLS Apr 28, 2019 Abandoned
Array ( [id] => 16596582 [patent_doc_number] => 20210023113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => CONJUGATE OF CYTOTOXIC DRUG AND PRODRUG FORM OF SAID CONJUGATE [patent_app_type] => utility [patent_app_number] => 17/042221 [patent_app_country] => US [patent_app_date] => 2019-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17042221 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/042221
CONJUGATE OF CYTOTOXIC DRUG AND PRODRUG FORM OF SAID CONJUGATE Apr 1, 2019 Pending
Array ( [id] => 16343578 [patent_doc_number] => 20200308228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => PEPTIDE INHIBITORS OF HCV NS3/4A PROTEASE COMPRISING NON-PROTEINOGENIC AMINO RESIDUES [patent_app_type] => utility [patent_app_number] => 16/371610 [patent_app_country] => US [patent_app_date] => 2019-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14610 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 168 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16371610 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/371610
PEPTIDE INHIBITORS OF HCV NS3/4A PROTEASE COMPRISING NON-PROTEINOGENIC AMINO RESIDUES Mar 31, 2019 Abandoned
Array ( [id] => 14682333 [patent_doc_number] => 20190240281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => ORAL ANAEROBIC GLUTATHIONE SUPPLEMENT IN LIPOSOME SUSPENSION [patent_app_type] => utility [patent_app_number] => 16/368057 [patent_app_country] => US [patent_app_date] => 2019-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16368057 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/368057
ORAL ANAEROBIC GLUTATHIONE SUPPLEMENT IN LIPOSOME SUSPENSION Mar 27, 2019 Abandoned
Array ( [id] => 20142857 [patent_doc_number] => 12377172 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-05 [patent_title] => Methods and compositions for the detection of cancer [patent_app_type] => utility [patent_app_number] => 16/365166 [patent_app_country] => US [patent_app_date] => 2019-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 7445 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16365166 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/365166
Methods and compositions for the detection of cancer Mar 25, 2019 Issued
Array ( [id] => 15020869 [patent_doc_number] => 20190321439 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/356259 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16356259 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/356259
FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE Mar 17, 2019 Abandoned
Array ( [id] => 16539455 [patent_doc_number] => 20200405868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => GEL-FORMING POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 16/970894 [patent_app_country] => US [patent_app_date] => 2019-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27709 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16970894 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/970894
GEL-FORMING POLYPEPTIDES Mar 13, 2019 Abandoned
Array ( [id] => 19624156 [patent_doc_number] => 12162960 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => Selectin inhibitors, composition, and uses related thereto [patent_app_type] => utility [patent_app_number] => 16/352585 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 8450 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16352585 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/352585
Selectin inhibitors, composition, and uses related thereto Mar 12, 2019 Issued
Array ( [id] => 16539502 [patent_doc_number] => 20200405915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => HYDROGEL FOR STIMULATING NEUROTIZATION, OSTEOGENESIS AND ANGIOGENESIS [patent_app_type] => utility [patent_app_number] => 16/976482 [patent_app_country] => US [patent_app_date] => 2019-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6963 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16976482 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/976482
HYDROGEL FOR STIMULATING NEUROTIZATION, OSTEOGENESIS AND ANGIOGENESIS Feb 27, 2019 Pending
Array ( [id] => 15206355 [patent_doc_number] => 20190365864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => TREATMENT OF PEDIATRIC TYPE 2 DIABETES MELLITUS PATIENTS [patent_app_type] => utility [patent_app_number] => 16/266873 [patent_app_country] => US [patent_app_date] => 2019-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28170 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16266873 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/266873
TREATMENT OF PEDIATRIC TYPE 2 DIABETES MELLITUS PATIENTS Feb 3, 2019 Abandoned
Array ( [id] => 16655844 [patent_doc_number] => 20210052480 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => USE OF CYCLIC PEPTIDES IN COSMETIC [patent_app_type] => utility [patent_app_number] => 16/963578 [patent_app_country] => US [patent_app_date] => 2019-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15760 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16963578 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/963578
USE OF CYCLIC PEPTIDES IN COSMETIC Jan 28, 2019 Pending
Array ( [id] => 14622025 [patent_doc_number] => 20190224380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-25 [patent_title] => COMPOSITIONS AND METHODS FOR ENHANCING HEALING AND REGENERATION OF BONE AND SOFT TISSUE [patent_app_type] => utility [patent_app_number] => 16/249748 [patent_app_country] => US [patent_app_date] => 2019-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10751 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16249748 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/249748
COMPOSITIONS AND METHODS FOR ENHANCING HEALING AND REGENERATION OF BONE AND SOFT TISSUE Jan 15, 2019 Pending
Array ( [id] => 14581285 [patent_doc_number] => 20190218251 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => DEUTERATED COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCERS ASSOCIATED WITH ETBR ACTIVATION [patent_app_type] => utility [patent_app_number] => 16/246398 [patent_app_country] => US [patent_app_date] => 2019-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16246398 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/246398
Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation Jan 10, 2019 Issued
Array ( [id] => 16398781 [patent_doc_number] => 20200339639 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => TREATMENT OF FRAGILE X SYNDROME [patent_app_type] => utility [patent_app_number] => 16/961345 [patent_app_country] => US [patent_app_date] => 2019-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14301 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16961345 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/961345
TREATMENT OF FRAGILE X SYNDROME Jan 9, 2019 Abandoned
Menu